<i>In vitro</i> modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant <i>EGFR</i> mutants in non-small-cell lung cancer
Toshiyuki Hirano(Sapporo Kosei General Hospital), Kenzo Soejima(Keio University), Shigenari Nukaga(Tokyo Medical Center), Tetsuo Tani(Keio University), Daniel B. Costa(Beth Israel Deaconess Medical Center), Kota Ishioka(Keio University), Masayoshi Miyawaki(Keio University), Tomoko Betsuyaku(Tokyo Medical University), Daisuke Arai(Keio University), Hiroyuki Yasuda(Beth Israel Deaconess Medical Center), Junko Hamamoto(Keio University), Ichiro Kawada(Keio University), Katsuhiko Naoki(Broad Institute), Susumu Kobayashi(Beth Israel Deaconess Medical Center), Ayano Oashi(Keio University)
Cited by 159
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Assessment of Resistance Mechanisms and Clinical Implications in Patients With<i>EGFR</i>T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib
|JAMA Oncology|2018|689
CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib
|Journal of Clinical Oncology|2011|590
Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer
|Science Translational Medicine|2013|565